Sugi Predict

Sugi Predict / Targets / CAMKK1

CAMKK1

Calcium/calmodulin-dependent protein kinase kinase 1 · Q8N5S9 · CAMKK1 on Sugi Atlas →

8,817 patent compounds predicted against CAMKK1, 2,671 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL448284 SCHEMBL448284 0.47 12/20
SCHEMBL1620627 SCHEMBL1620627 0.47 11/20
SCHEMBL3443366 SCHEMBL3443366 0.47 11/20
SCHEMBL9842402 SCHEMBL9842402 0.42 10/20
SCHEMBL7821778 SCHEMBL7821778 0.50 9/20
SCHEMBL9250275 SCHEMBL9250275 0.49 9/20
SCHEMBL2731512 SCHEMBL2731512 0.48 7/20
SCHEMBL50486 SCHEMBL50486 0.47 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL10630457) 0.45 7/20
SCHEMBL3844913 SCHEMBL3844913 0.48 6/20
SCHEMBL10634854 SCHEMBL10634854 0.46 6/20
SCHEMBL10634926 SCHEMBL10634926 0.46 6/20
SCHEMBL3634253 SCHEMBL3634253 0.45 6/20
SCHEMBL9251164 SCHEMBL9251164 0.42 6/20
Gsk-650394 Gsk-650394 (SCHEMBL3767908) 1.00 4/20
SCHEMBL182560 SCHEMBL182560 0.52 4/20
SCHEMBL182932 SCHEMBL182932 0.52 4/20
SCHEMBL3847833 SCHEMBL3847833 0.47 4/20
SCHEMBL8867391 SCHEMBL8867391 0.46 4/20
SCHEMBL4710750 SCHEMBL4710750 0.40 4/20

Clinical trials — most relevant to CAMKK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
COMS for Chronic Ulcers Treatment PHASE4RECRUITING
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction PHASE2UNKNOWN
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction PHASE2ACTIVE_NOT_RECRUITING
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients PHASE1COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia nanRECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Ischemic Preconditioning to Prevent Acute Kidney Injury nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease nanUNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients nanUNKNOWN
Effect of Age on Glucose and Lipid Metabolism nanCOMPLETED
Biomarkers of CASH nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CAMKK1 binder may also engage these)

ProteinNameSimilarity
Q8VBY2 — 1.000 Q8VBY2 →
P97756 — 1.000 P97756 →
O88831 — 0.992 O88831 →
Q8C078 — 0.990 Q8C078 →
P13234 — 0.990 P13234 →
CAMKK2 Calcium/calmodulin-dependent protein kinase kinase 2 0.989 landscape →
Q91VB2 — 0.989 Q91VB2 →
Q5RJI5 — 0.989 Q5RJI5 →
B2DD29 — 0.988 B2DD29 →
STK32C Serine/threonine-protein kinase 32C 0.987 landscape →
MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 0.987 landscape →
Q8CIP4 — 0.987 Q8CIP4 →
GAK Cyclin-G-associated kinase 0.987 landscape →
P97874 — 0.986 P97874 →
RPS6KB1 Ribosomal protein S6 kinase beta-1 0.986 landscape →
A5PKJ4 — 0.986 A5PKJ4 →
Q3ULB5 — 0.986 Q3ULB5 →
BRSK1 Serine/threonine-protein kinase BRSK1 0.986 landscape →
Q8BSK8 — 0.986 Q8BSK8 →
Q6TJY3 — 0.986 Q6TJY3 →
Q641K5 — 0.986 Q641K5 →
Q99KY4 — 0.986 Q99KY4 →
PHKG2 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform 0.986 landscape →
CAMK4 Calcium/calmodulin-dependent protein kinase type IV 0.985 landscape →
Q69Z98 — 0.985 Q69Z98 →
BRSK2 Serine/threonine-protein kinase BRSK2 0.985 landscape →
P08414 — 0.985 P08414 →
Q68UT7 — 0.985 Q68UT7 →
Q8RXT4 — 0.984 Q8RXT4 →
Q6PGN3 — 0.984 Q6PGN3 →